Next Article in Journal
Antibody Responses to Marburg Virus in Egyptian Rousette Bats and Their Role in Protection against Infection
Previous Article in Journal
Nonstructural Proteins of Alphavirus—Potential Targets for Drug Development
Open AccessArticle

Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models

by 1,†, 1,†, 2,* and 1,*
1
Department of Biomedical Sciences, College of Medicine, Korea University Guro Hospital, Seoul 08308, Korea
2
Department of Tropical Medicine, Medical Microbiology and Pharmacology, Pacific Center for Emerging Infectious Diseases Research, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA
*
Authors to whom correspondence should be addressed.
These two authors contributed equally to this work.
Viruses 2018, 10(2), 72; https://doi.org/10.3390/v10020072
Received: 3 January 2018 / Revised: 29 January 2018 / Accepted: 8 February 2018 / Published: 9 February 2018
(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
Zika virus (ZIKV) has recently emerged as a new public health threat. ZIKV infections have caused a wide spectrum of neurological diseases, such as Guillain–Barré syndrome, myelitis, meningoencephalitis, and congenital microcephaly. No effective therapies currently exist for treating patients infected with ZIKV. Herein, we evaluated the anti-viral activity of favipiravir (T-705) and ribavirin against Asian and African strains of ZIKV using different cell models, including human neuronal progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma cells (A549) and Vero cells. Cells were treated with favipiravir or ribavirin and effects on ZIKV replication were determined using quantitative real-time PCR and plaque assay. Our results demonstrate that favipiravir or ribavirin treatment significantly inhibited ZIKV replication in a dose-dependent manner. Moreover, favipiravir treatment of ZIKV-infected hNPCs led to reduced cell death, enhanced AKT pathway phosphorylation, and increased expression of anti-apoptotic factor B cell lymphoma 2. In conclusion, our results demonstrate conclusively that favipiravir inhibits ZIKV replication and prevents cell death, and can be a promising intervention for ZIKV-associated disease. View Full-Text
Keywords: favipiravir; ribavirin; Zika virus; hNPCs; anti-viral favipiravir; ribavirin; Zika virus; hNPCs; anti-viral
Show Figures

Figure 1

MDPI and ACS Style

Kim, J.-A.; Seong, R.-K.; Kumar, M.; Shin, O.S. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models. Viruses 2018, 10, 72. https://doi.org/10.3390/v10020072

AMA Style

Kim J-A, Seong R-K, Kumar M, Shin OS. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models. Viruses. 2018; 10(2):72. https://doi.org/10.3390/v10020072

Chicago/Turabian Style

Kim, Ji-Ae; Seong, Rak-Kyun; Kumar, Mukesh; Shin, Ok S. 2018. "Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models" Viruses 10, no. 2: 72. https://doi.org/10.3390/v10020072

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop